PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

CJEU clarifies jurisdiction rules for European patent enforcement: BSH Hausgeräte vs. Electrolux AB

  • Sector: Patent law
  • 1st March 2025
 

Originally posted on IPKat.

Earlier this week the CJEU provided its ruling in the highly anticipated case of BSH Hausgeräte v. Electrolux (Case C-339/22, February 2025). The case addressed longstanding questions about the jurisdiction of European courts when patent invalidity is raised as a defence in an infringement case. The CJEU found that national courts maintain jurisdiction over infringement claims against defendants domiciled in their territory, even when invalidity of foreign patents is raised. The case follows a recent UPC case that tackled similar questions relating to the jurisdiction of the UPC to hear cases relating to UK patent infringement (UPC_CFI_355/2023). 

BSH sued Electrolux (a Swedish company) in Sweden. BSH alleged that Electrolux infringed its EP1434512 (relating to vacuum cleaners) which was validated in certain EU states and Turkey. BSH requested an injunction and damages for infringement in all these countries. In response, Electrolux argued that the patents were invalid and that the court had no jurisdiction, claiming that Article 24(4) of the Brussels Regulation meant that if invalidity was raised, the court would lose jurisdiction over the infringement case. 

Article 4(1) Brussels I Regulation (Regulation 1215/2012) states that “persons domiciled in a Member State shall, whatever their nationality, be sued in the courts of that Member State“. 

Article 24 Brussels I Regulation (Regulation 1215/2012) states that: “The following courts of a Member State shall have exclusive jurisdiction, regardless of the domicile of the parties […] (4) in proceedings concerned with the registration or validity of patents […] irrespective of whether the issue is raised by way of an action or as a defence, the courts of the Member State in which the deposit or registration has been applied for“. 

The Swedish court of appeal referred the following questions to the CJEU: 

1. Does a court that has jurisdiction for patent infringement under Article 4(1) of the Regulation lose its jurisdiction if the validity of the patent is contested? Or does the court only have jurisdiction to decide on validity?

2. Is it relevant whether national law requires a separate invalidity action?

3. Does Article 24(4) of the Regulation also apply to courts of third countries (here: Turkey)?

The CJEU ruled in BSH’s favour, finding that Article 24(4) should be strictly interpreted as an exception to the general rule of Article 4(1). The CJEU particularly found that whilst national courts cannot rule on the validity of foreign patents, they can continue hearing infringement claims, with the option to stay proceedings if there’s a reasonable possibility the patent might be invalidated in its country of registration. The CJEU concluded that under Article 4(1), the court in which the defendant is domiciled remains competent to decide on patent infringement, even if the patent was granted in another European state and even if the validity of the patent is contested. At the same time, the CJEU confirmed the exclusive jurisdiction of the courts of the patent-granting state to decide on the validity of the patent. 

Therefore, according to the CJEU decision, EU courts (including the UPC) can look at the question of validity of European patents in non-EU countries to determine infringement issues. However, the EU court’s decision will not affect the existence or content of the patent in that third country (para. 74).

Related insights...

ViCo oral proceedings: Whatever happened to the in-person “Gold-Standard”?

  • 14th December 2025
We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21? 

UPC Court of Appeal tackles broad functional antibody claims (UPC_CoA_529/2024)

  • 4th December 2025
The global litigation saga involving Amgen’s PCSK9 antibodies has long served as a high-stakes test case for jurisdictional approaches to broad, functionally defined antibody claims. Following the US Supreme Court’s landmark finding of lack of enablement in Amgen v Sanofi, and the UPC Munich Central Division’s initial revocation of the equivalent European patent, all eyes…

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector field is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025 (see Evolve Insights), we review the most impactful decisions of the year relating to clinical-stage inventions. 

EPO pharma case law trends 2025: Antibodies and biologics

  • 19th November 2025
The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted design and in silico modelling. Patent law must respond to these new challenges. What better time to take a look at the trends from the EPO case…

Insufficiency resulting from mutually exclusive definitions: The repercussive effect of dependent claims (T 0878/23)

  • 18th November 2025
In T 0878/23, the Board of Appeal ruled that mutually exclusive ranges in dependent claims constitute fatal insufficiency rather than a mere lack of clarity. This decision underscores the “repercussive effect” of claim dependencies, warning that internal contradictions can make an invention technically impossible to perform.

First use of G 1/24 to broaden clear claim language (T 1849/23)

  • 16th November 2025
This significant decision is the first from the Boards of Appeal to apply G 1/24 to the use of information from the description to broaden otherwise clear claim language.

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.

The unforgiving gold standard: Why deleting a feature can add matter at the EPO (T 0422/23)

  • 30th September 2025
Addition by subtraction: How deleting a feature from a patent claim can fall foul of the EPO’s unforgiving rules on added matter.

The party’s over: EBA leaves late interveners stranded (G2/24)

  • 26th September 2025
Can a third party intervener take over a withdrawn appeal at the EPO? The EBA gives a clear ‘No’.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us